Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

被引：223
|
作者：
Aldoss, Ibrahim [1 ]
Yang, Dongyun [2 ]
Aribi, Ahmed [1 ]
Ali, Haris [1 ]
Sandhu, Karamjeet [1 ]
Al Malki, Monzr M. [1 ]
Mei, Matthew [1 ]
Salhotra, Amandeep [1 ]
Khaled, Samer [1 ]
Nakamura, Ryotaro [1 ]
Snyder, David [1 ]
O'Donnell, Margaret [1 ]
Stein, Anthony S. [1 ]
Forman, Stephen J. [1 ]
Marcucci, Guido [1 ]
Pullarkat, Vinod [1 ]
机构：
[1] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Dept Hematol & Hematopoiet Cell Transplant, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Informat Sci, Div Biostat, Duarte, CA USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 09期
关键词：
CONVENTIONAL CARE REGIMENS; OLDER PATIENTS; AZACITIDINE; AML; RECOMMENDATIONS; DIAGNOSIS; TARGETS;
D O I：
10.3324/haematol.2018.188094
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E404 / E407
页数：4
相关论文
共 50 条
  • [21] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
    Che, Yue
    Tan, Wanqing
    Liu, Ying
    Liu, Haitao
    Li, Lanlan
    Qin, Fangmei
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
  • [22] Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
    Saliba, Antoine N.
    John, August J.
    Kaufmann, Scott H.
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 125 - 142
  • [23] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
  • [24] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
  • [25] Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases
    Wang, Na
    He, Jing
    Liu, Fang
    CHEMOTHERAPY, 2022, 67 (03) : 178 - 182
  • [26] Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Benjamin, David J.
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph M.
    Jonas, Brian A.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
    Shahswar, Rabia
    Gabdoulline, Razif
    Krueger, Katja
    Wichmann, Martin
    Goetze, Katharina S.
    Braitsch, Krischan
    Meggendorfer, Manja
    Schmalbrock, Laura
    Bullinger, Lars
    Modemann, Franziska
    Fiedler, Walter
    Krauter, Juergen
    Kaun, Stephan
    Rotermund, Susanne
    Voss, Andreas
    Behrens, Yvonne Lisa
    Bergmann, Anke Katharina
    Koller, Elisabeth
    Beutel, Gernot
    Thol, Felicitas
    Heidel, Florian
    Heuser, Michael
    LEUKEMIA, 2025, 39 (03) : 614 - 622
  • [28] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [29] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [30] Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2021, 138
12345